Bionic eyes move toward reality as Prima and ReVision implants advance

A Conversation overview of retinal implants: Prima restored functional central vision to 81% of patients with dry AMD and is authorized in 30 European countries, while Belgium's ReVision Implant begins its first human trial in October 2026. Earlier devices Argus II and Retina Implant AG were discontinued in 2019.

• Prima restored functional central vision in 81% of dry AMD patients
• The Prima implant is authorized in 30 European countries
• ReVision Implant starts its first human clinical trial in October 2026
• Argus II with 60 electrodes and Retina Implant AG shut down in 2019